Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600 Mutation Positive Melanoma”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Not applicableNo Longer AvailableNCT04544202
What this trial is testing

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Who this might be right for
MelanomaAdjuvant
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01972347
What this trial is testing

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 35
Not applicableStudy completedNCT06337617
What this trial is testing

A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Who this might be right for
BRAF V600 Mutation Positive Melanoma
Novartis Pharmaceuticals 90
Early research (Phase 1)Looking for participantsNCT04913285
What this trial is testing

Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Who this might be right for
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Study completedNCT02083354
What this trial is testing

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Who this might be right for
CancerMelanoma
Novartis Pharmaceuticals 77
Testing effectiveness (Phase 2)UnknownNCT03514901
What this trial is testing

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Who this might be right for
Melanoma MetastaticBRAF V600 Mutation
Intergruppo Melanoma Italiano 120
Early research (Phase 1)Study completedNCT02608034
What this trial is testing

Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Genentech, Inc. 32
Early research (Phase 1)Ended earlyNCT01400451
What this trial is testing

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Who this might be right for
Melanoma
Bristol-Myers Squibb 18
Early research (Phase 1)Study completedNCT02082665
What this trial is testing

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Who this might be right for
Cancer
GlaxoSmithKline 6
Not applicableActive Not RecruitingNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Not applicableStudy completedNCT03139513
What this trial is testing

Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

Who this might be right for
Melanoma
Hoffmann-La Roche 200
Not applicableStudy completedNCT01990248
What this trial is testing

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 339
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Large-scale testing (Phase 3)Looking for participantsNCT07440290
What this trial is testing

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+17 more
Cancer Research UK 30
Large-scale testing (Phase 3)Study completedNCT01682083
What this trial is testing

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

Who this might be right for
Melanoma
Novartis Pharmaceuticals 870
Testing effectiveness (Phase 2)Active Not RecruitingNCT04074096
What this trial is testing

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis

Who this might be right for
Malignant MelanomaBRAF V600 MutationBrain Metastases
UNICANCER 10
Large-scale testing (Phase 3)Study completedNCT03551626
What this trial is testing

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Who this might be right for
Malignant Melanoma
Novartis Pharmaceuticals 552
Post-approval studies (Phase 4)Study completedNCT01898585
What this trial is testing

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 60
Not applicableActive Not RecruitingNCT04666272
What this trial is testing

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Who this might be right for
Melanoma
Novartis Pharmaceuticals 78
Early research (Phase 1)Study completedNCT01954043
What this trial is testing

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Who this might be right for
Cancer
GlaxoSmithKline 23
Next Page